home / stock / abos / abos news

ABOS News and Press, Acumen Pharmaceuticals Inc.

Stock Information
Company Name: Acumen Pharmaceuticals Inc.
Stock Symbol: ABOS
Market: NASDAQ
Website: acumenpharm.com
Menu
ABOS ABOS Quote ABOS Short ABOS News ABOS Articles ABOS Message Board
Get ABOS Alerts

News, Short Squeeze, Breakout and More Instantly...
ABOS - Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

2024-07-29 20:38:51 ET Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ...
ABOS - Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer’s disease (AD),&...

ABOS - Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...

ABOS - Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
ABOS - Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript

2024-05-14 12:46:06 ET Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Conference Call May 14, 2024 08:00 ET Company Participants Alex Braun - Vice President & Head of Investor Relations Daniel O’Connell - Chief Executive Officer Matt Zuga - Chief...

ABOS - Acumen Pharmaceuticals GAAP EPS of -$0.25

2024-05-14 07:01:38 ET More on Acumen Pharmaceuticals Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Acumen Pharmaceuticals partners with Lonza to advance sabirnetug for...

ABOS - Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalent...
ABOS - Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...

ABOS - Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...

ABOS - Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD),&#...
Next 10